Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs
2015; Massachusetts Medical Society; Volume: 373; Issue: 27 Linguagem: Inglês
10.1056/nejme1513245
ISSN1533-4406
AutoresJohn W. Ward, Jonathan Mermin,
Tópico(s)Liver Disease Diagnosis and Treatment
ResumoThe results of four clinical trials showing the excellent safety and efficacy of a 12-week course of sofosbuvir (an NS5B inhibitor licensed in the United States in 2013) and velpatasvir (a new NS5A inhibitor) in treating patients with hepatitis C infection (HCV) are reported now in the Journal.13 In two of these studies, ASTRAL-1 and ASTRAL-2, 97 to 100% of patients with HCV genotype 1a, 1b, 2, 4, 5, or 6 had a sustained virologic response at 12 weeks after the end of therapy, a marker that is indicative of virologic cure. Similar efficacy was observed among patients . . .
Referência(s)